Overview

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Status:
Recruiting
Trial end date:
2023-08-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
LY3298176
Tirzepatide